EMA Refused: Labazenit (Budesonide;salmeterol) — Laboratoires SMB S.A.

View source ↗

Summary

The EMA refused approval for Labazenit (budesonide; salmeterol) for asthma from Laboratoires SMB S.A., with a decision dated 22 March 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Labazenit (budesonide; salmeterol)

Snippet

Status: Refused. Therapeutic area: Asthma. MAH: Laboratoires SMB S.A.. Decision date: 22/03/2013